Acceder

Vaxart. Candidata vacuna covid

81 respuestas
Vaxart. Candidata vacuna covid
4 suscriptores
Vaxart. Candidata vacuna covid
Página
1 / 6
#1

Vaxart. Candidata vacuna covid

Vaxart sube un 27% en el mercado previo al alentar los datos de la vacuna COVID-19

21 de abril de 2020 8:15 a.m. ET Vaxart, Inc. ( VXRT ) 1 comentario
  • Vaxart (NASDAQ: VXRTaumenta un 27%  en el mercado previo en un volumen robusto en reacción a su anuncio de datos preclínicos positivos sobre sus candidatos a la vacuna oral COVID-19.
  • La compañía dice que varios candidatos provocaron respuestas inmunitarias en todos los animales probados después de una sola dosis, acción comparable a su vacuna contra la gripe oral. Específicamente, todos los animales que recibieron un candidato desarrollaron anticuerpos IgG contra el virus SARS-CoV-2 dos semanas después de la primera vacunación. Las respuestas de anticuerpos en todos los grupos vacunados fueron estadísticamente significativas en comparación con los controles no tratados.
  • La compañía planea seleccionar uno o más candidatos para un mayor desarrollo basado en la mayor inmunogenicidad observada.

#2

Re: Vaxart. Candidata vacuna covid

+35%
#3

Re: Vaxart. Candidata vacuna covid

+45%
#4

Re: Vaxart. Candidata vacuna covid

  #Vaxart inició estudios preclínicos para una vacuna COVID-19 en enero tras los informes de la propagación del brote en todo el mundo. El candidato se basa en la plataforma de vacunas orales VAASTT de la compañía, que utiliza adenovirus tipo 5 (Ad5) como sistema de administración para su tratamiento. En esta primera ronda de pruebas preclínicas, todos los animales que recibieron una de las vacunas Vaxart tenían anticuerpos IgG anti-SARS CoV-2 en suero dos semanas después de la primera vacunación. Las respuestas de anticuerpos en todos los grupos vacunados fueron estadísticamente significativas en comparación con los controles no tratados, dijo Vaxart esta mañana. Ahora, la compañía planea seleccionar uno o más candidatos a vacunas para la fabricación de cGMP y las pruebas clínicas en función de la magnitud y la amplitud de la respuesta inmune.

Wouter Latour, director ejecut un Vaxart, calificó los resultados del estudio preclínico como alentadores y dijo que la compañía estará en condiciones de seleccionar a su candidato para el desarrollo en las próximas semanas.

"Se ha demostrado que nuestras vacunas orales protegen contra la infección respiratoria basada en la inmunidad de la mucosa, la primera línea de defensa para tales infecciones, como se publicó recientemente en Lancet Infectious Diseases . Esto podría ser importante para una vacuna eficaz que proteja a la población mundial de COVID-19. Además, la vacuna Vaxart se administraría por vía oral utilizando una tableta estable a temperatura ambiente, una enorme ventaja logística sobre los inyectables en grandes campañas de vacunación ", dijo Latour en un comunicado.

Para Vaxart, la noticia preclínica positiva llega aproximadamente un mes después de que la compañía suscribió un acuerdo de desarrollo con Emergent BioSolutions Inc. para prepararse para la producción de cGMP de una vacuna oral COVID-19. La primera etapa de la colaboración está en marcha y, siempre que Vaxart elija proceder con la fabricación de cGMP, se espera que Emergent produzca la vacuna cGMP a granel a tiempo para permitir el inicio de un estudio clínico de Fase I durante la segunda mitad de 2020, dijo la compañía

https://www.biospace.com/article/wit...to-the-clinic/

   |




|   | Inicio | ForoCoches > Zona General > InverForo  Panel de Control Mensajes Privados Suscripciones Buscar Foros Foros Home      Zona General      General      Electrónica / Informática          Fotografía              Compra - Venta Fotografía      Empleo / Emprendimiento          Taxis / VTCs      Viajes      Quedadas (KDD)      InverForo  Zona ForoCoches      ForoCoches      Competición      Eléctricos      Clásicos          Compra - Venta Clasicos      Monovolúmenes      4x4 / Ocio          Compra - Venta 4x4 / Ocio      Modelismo          Compra - Venta Modelismo      Camiones / Furgones / Autobuses      Motos          Compra - Venta Motos  Zona Técnica 
Respuesta RápidaMensaje:
|
|
|
|
|
|

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|   |
OpcionesAuto-Guardado: Activo¿Citar mensiOS | ANDROID ]




#5

Re: Vaxart. Candidata vacuna covid

 

Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program

April 21, 2020 at 8:00 AM EDT
Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First Dose
SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose.

“These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study,” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “Additional data will inform us on which candidate we will move forward into clinical trials. We are particularly interested in vaccine candidates that can generate mucosal immune responses in addition to serum antibody responses. That is a key feature of our oral vaccines and potentially significant for protection against SARS CoV-2, the virus that causes COVID-19.” 

In January 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM oral vaccines platform. The Company is currently evaluating multiple vaccine candidates in its preclinical models. In this first round of preclinical testing, all animals that received one of the Vaxart vaccines had IgG anti-SARS CoV-2 antibodies in serum two weeks after the first vaccination. Antibody responses in all vaccinated groups were statistically significant compared to the untreated controls. Vaxart plans to select one or more vaccine candidates for cGMP manufacturing and clinical testing based on the magnitude and the breadth of the immune response.

On March 18, 2020, Vaxart entered into an agreement with Emergent BioSolutions Inc. (“Emergent”) for development services to prepare for cGMP production of an oral COVID-19 vaccine. The first stage of the collaboration is underway and, provided Vaxart elects to proceed with cGMP manufacturing, Emergent is expected to produce bulk cGMP vaccine in time to allow the initiation of a Phase 1 clinical study during the second half of 2020.

“These results are extremely encouraging, and we should be in a position to select a lead development candidate for cGMP manufacturing and clinical testing in the coming weeks,” said Wouter Latour, MD, chief executive officer of Vaxart Inc. “Our oral vaccines have been shown to protect against respiratory infection based on mucosal immunity, the first line of defense for such infections, as recently published in the Lancet Infectious Diseases. This could be important for an effective vaccine that protects the global population from COVID-19. In addition, the Vaxart vaccine would be administered orally using a room temperature-stable tablet, an enormous logistical advantage over injectables in large vaccination campaigns.” 

About Vaxart
Vaxart is a clinical-stage biotechnology company primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (“RSV”), as well as a therapeutic vaccine for human papillomavirus (“HPV”). For more information, please visit www.vaxart.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent, including Emergent’s ability to produce bulk cGMP vaccine and the timing thereof; and Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and SARS CoV-2. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s control, including the recent outbreak of COVID-19; that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

Contact
Brant Biehn
Vaxart Inc
650 550 3500
[email protected] 


#6

Re: Vaxart. Candidata vacuna covid

¿Cuántas veces vas a poner lo mismo?
#8

Re: Vaxart. Candidata vacuna covid

Compra antes de que se ponga en 8 dólares
#10

Re: Vaxart. Candidata vacuna covid

Sube con fuerza
#11

Re: Vaxart. Candidata vacuna covid

+14%, a ver si hoy es capaz de subir otro 35%
#12

Re: Vaxart. Candidata vacuna covid

A punto de romper la resistencia de 3,16

 
 
#13

Re: Vaxart. Candidata vacuna covid

Vaxart

Vaxart es sin duda una de las compañías más beneficiadas en bolsa como consecuencia del Covid-19. La empresa biotecnológica, con sede en San Francisco, cotizaba a principios de año en los 0,36 dólares por acción. Desde entonces la compañía ya anunció que estaba desarrollando una vacuna.

No fue hasta marzo cuando se hizo pública su alianza con Emergent Biosolutions, lo que catapultó su cotización. La compañía ha asegurado que comenzará sus ensayos clínicos de su vacuna oral en la segunda mitad de 2020. Esto ha hecho que su cotización supere los 2,6 dólares, es decir, una revalorización desde principios de año de más del 640%.
https://www.elespanol.com/invertia/mercados/20200427/carrera-lucha-coronavirus-pone-foco-bursatil-farmaceuticas/484952266_0.html
#15

Re: Vaxart. Candidata vacuna covid

Fiesta en preapertura